Pure Bioscience Inc
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. Its technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. The comp… Read more
Pure Bioscience Inc (PURE) - Net Assets
Latest net assets as of January 2025: $-4.27 Million USD
Based on the latest financial reports, Pure Bioscience Inc (PURE) has net assets worth $-4.27 Million USD as of January 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($574.00K) and total liabilities ($4.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.27 Million |
| % of Total Assets | -743.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -159.53% |
| 10-Year Change | -220.18% |
| Growth Volatility | 2695.29 |
Pure Bioscience Inc - Net Assets Trend (1996–2024)
This chart illustrates how Pure Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pure Bioscience Inc (1996–2024)
The table below shows the annual net assets of Pure Bioscience Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-07-31 | $-2.86 Million | -1152.94% |
| 2023-07-31 | $272.00K | -93.04% |
| 2022-07-31 | $3.91 Million | +17.28% |
| 2021-07-31 | $3.33 Million | -30.72% |
| 2020-07-31 | $4.81 Million | +304.29% |
| 2019-07-31 | $1.19 Million | -7.10% |
| 2018-07-31 | $1.28 Million | -0.70% |
| 2017-07-31 | $1.29 Million | -74.32% |
| 2016-07-31 | $5.02 Million | +110.78% |
| 2015-07-31 | $2.38 Million | +13917.65% |
| 2014-07-31 | $17.00K | +101.72% |
| 2013-07-31 | $-991.00K | -221.15% |
| 2012-07-31 | $818.00K | -80.56% |
| 2011-07-31 | $4.21 Million | -21.99% |
| 2010-07-31 | $5.39 Million | -23.66% |
| 2009-07-31 | $7.07 Million | -28.93% |
| 2008-07-31 | $9.94 Million | +128.08% |
| 2007-07-31 | $4.36 Million | -42.28% |
| 2006-07-31 | $7.55 Million | +155.12% |
| 2005-07-31 | $2.96 Million | +21.62% |
| 2004-07-31 | $2.43 Million | -27.80% |
| 2003-07-31 | $3.37 Million | 0.00% |
| 2002-07-31 | $3.37 Million | -2.55% |
| 2001-07-31 | $3.46 Million | -24.84% |
| 2000-07-31 | $4.60 Million | +58.73% |
| 1999-07-31 | $2.90 Million | +38.10% |
| 1998-07-31 | $2.10 Million | -40.00% |
| 1997-07-31 | $3.50 Million | +3600.00% |
| 1996-07-31 | $-100.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pure Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13579500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.12 Million | % |
| Other Components | $132.61 Million | % |
| Total Equity | $-2.86 Million | 100.00% |
Pure Bioscience Inc Competitors by Market Cap
The table below lists competitors of Pure Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brisbane Broncos Ltd
AU:BBL
|
$4.93 Million |
|
CDT Environmental Technology Investment Holdings Limited ordinary shares
NASDAQ:CDTG
|
$4.93 Million |
|
PT Cipta Perdana Lancar Tbk
JK:PART
|
$4.93 Million |
|
Chia Yi Steel Co Ltd
TWO:2067
|
$4.93 Million |
|
NIPPON PROLOGIS REIT INC.
F:9NPA
|
$4.93 Million |
|
LEGEND POWER SYS INC.
F:XLE1
|
$4.92 Million |
|
Cauldron Energy Limited
PINK:CAULF
|
$4.92 Million |
|
Tarena International Inc
NASDAQ:TCTM
|
$4.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pure Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 272,000 to -2,864,000, a change of -3,136,000 (-1152.9%).
- Net loss of 3,350,000 reduced equity.
- Other factors increased equity by 214,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.35 Million | -116.97% |
| Other Changes | $214.00K | +7.47% |
| Total Change | $- | -1152.94% |
Book Value vs Market Value Analysis
This analysis compares Pure Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-07-31 | $-0.28 | $0.08 | x |
| 1997-07-31 | $8.40 | $0.08 | x |
| 1998-07-31 | $4.33 | $0.08 | x |
| 1999-07-31 | $4.55 | $0.08 | x |
| 2000-07-31 | $4.50 | $0.08 | x |
| 2001-07-31 | $4.35 | $0.08 | x |
| 2002-07-31 | $3.53 | $0.08 | x |
| 2003-07-31 | $3.53 | $0.08 | x |
| 2004-07-31 | $1.59 | $0.08 | x |
| 2005-07-31 | $1.47 | $0.08 | x |
| 2006-07-31 | $2.95 | $0.08 | x |
| 2007-07-31 | $1.42 | $0.08 | x |
| 2008-07-31 | $2.89 | $0.08 | x |
| 2009-07-31 | $1.85 | $0.08 | x |
| 2010-07-31 | $1.25 | $0.08 | x |
| 2011-07-31 | $0.90 | $0.08 | x |
| 2012-07-31 | $0.15 | $0.08 | x |
| 2013-07-31 | $-0.09 | $0.08 | x |
| 2014-07-31 | $0.00 | $0.08 | x |
| 2015-07-31 | $0.06 | $0.08 | x |
| 2016-07-31 | $0.09 | $0.08 | x |
| 2017-07-31 | $0.02 | $0.08 | x |
| 2018-07-31 | $0.02 | $0.08 | x |
| 2019-07-31 | $0.02 | $0.08 | x |
| 2020-07-31 | $0.06 | $0.08 | x |
| 2021-07-31 | $0.04 | $0.08 | x |
| 2022-07-31 | $0.04 | $0.08 | x |
| 2023-07-31 | $0.00 | $0.08 | x |
| 2024-07-31 | $-0.03 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pure Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -170.66%
- • Asset Turnover: 2.40x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2843.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | -50.00% | 1.00x | 0.00x | $-390.00K |
| 1997 | -34.29% | -120.00% | 0.28x | 1.03x | $-1.55 Million |
| 1998 | -90.48% | -111.76% | 0.57x | 1.43x | $-2.11 Million |
| 1999 | 10.34% | 8.82% | 0.85x | 1.38x | $10.00K |
| 2000 | -40.19% | -109.86% | 0.32x | 1.14x | $-2.28 Million |
| 2001 | -51.51% | -73.96% | 0.59x | 1.18x | $-2.13 Million |
| 2002 | -80.82% | -84.99% | 0.71x | 1.35x | $-3.06 Million |
| 2003 | -80.82% | -84.99% | 0.71x | 1.35x | $-3.06 Million |
| 2004 | -97.81% | -903.58% | 0.05x | 2.25x | $-2.62 Million |
| 2005 | -62.39% | -1185.53% | 0.05x | 1.12x | $-2.14 Million |
| 2006 | -50.48% | -1902.35% | 0.03x | 1.05x | $-4.57 Million |
| 2007 | -106.77% | -1383.77% | 0.07x | 1.12x | $-5.09 Million |
| 2008 | -65.77% | -439.70% | 0.14x | 1.10x | $-7.53 Million |
| 2009 | -100.01% | -970.43% | 0.10x | 1.08x | $-7.77 Million |
| 2010 | -125.32% | -470.73% | 0.24x | 1.11x | $-7.30 Million |
| 2011 | -198.17% | -1796.53% | 0.09x | 1.22x | $-8.76 Million |
| 2012 | -1085.82% | -1093.84% | 0.18x | 5.45x | $-8.96 Million |
| 2013 | 0.00% | -1043.17% | 0.40x | 0.00x | $-8.45 Million |
| 2014 | -76188.24% | -2354.91% | 0.30x | 109.35x | $-12.95 Million |
| 2015 | -319.51% | -1044.44% | 0.22x | 1.37x | $-7.85 Million |
| 2016 | -431.71% | -1682.31% | 0.17x | 1.51x | $-22.19 Million |
| 2017 | -505.27% | -355.98% | 0.48x | 2.97x | $-6.65 Million |
| 2018 | -583.53% | -421.36% | 0.69x | 2.01x | $-7.60 Million |
| 2019 | -551.34% | -343.69% | 0.99x | 1.62x | $-6.68 Million |
| 2020 | -0.12% | -0.09% | 1.09x | 1.31x | $-487.10K |
| 2021 | -69.58% | -59.05% | 0.91x | 1.29x | $-2.65 Million |
| 2022 | -89.46% | -188.72% | 0.41x | 1.15x | $-3.89 Million |
| 2023 | -1456.25% | -211.03% | 1.03x | 6.71x | $-3.99 Million |
| 2024 | 0.00% | -170.66% | 2.40x | 0.00x | $-3.06 Million |
Industry Comparison
This section compares Pure Bioscience Inc's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,833,853,398
- Average return on equity (ROE) among peers: 27.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pure Bioscience Inc (PURE) | $-4.27 Million | 0.00% | N/A | $4.93 Million |
| Acme United Corporation (ACU) | $19.90 Million | 2.51% | 0.55x | $132.86 Million |
| Beiersdorf Aktiengesellschaft (BDRFF) | $3.02 Billion | 8.59% | 0.75x | $11.93 Billion |
| Science to Consumers Inc (BEUT) | $-3.05K | 0.00% | 0.00x | $1.09K |
| Société BIC SA (BICEY) | $1.70 Billion | 16.88% | 0.41x | $566.61 Million |
| Blue Moon Group Holdings Limited (BLUMY) | $12.35 Billion | 8.22% | 0.18x | $1.01 Billion |
| Bemax Inc (BMXC) | $-244.86K | 0.00% | 0.00x | $3.63K |
| Bruush Oral Care Inc. (BRSHF) | $-216.93K | 0.00% | 0.00x | $335.48 |
| Park Ha Biological Technology Co., Ltd. (BYAH) | $-578.18K | 0.00% | 0.00x | $11.97 Million |
| Church & Dwight Company Inc (CHD) | $284.43 Million | 16.52% | 2.34x | $22.97 Billion |
| Colgate-Palmolive Company (CL) | $971.00 Million | 223.07% | 14.49x | $67.85 Billion |